ムスカリン拮抗薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Muscarinic Antagonist Market Insights, Forecast to 2028

• レポートコード：QY2207E10420 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、126ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界のムスカリン拮抗薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にムスカリン拮抗薬の世界市場のxxx％を占める「アトロピン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院用」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のムスカリン拮抗薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのムスカリン拮抗薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのムスカリン拮抗薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 ムスカリン拮抗薬のグローバル主要メーカーには、Aseptic Innovative Medicine、OSRX Pharmaceuticals、Tache Pharmacy、Wufu Laboratories、Singapore National Eye Centre、Shenyang Xingqi Pharmaceutical、Aier Eye Hospital Group、He Eye Specialist Hospital、Alkaloids of Australia、Boehringer Ingelheim、Fine Chemicals Corporation、Phytex Australia、Alchem International、Guangzhou Hanfang、Alkaloids Corporation、Luyin、Toobapharma、Infa Group、Suven Life Sciences Limited、Sharon、Tai Heng Industry Co., Ltd、Stellar Chemical Laboratories Pvt、Invent Farma、Wuhan Shengtianyu、AstraZeneca、Synapse Pharma、Vectura Group、Elanなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 ムスカリン拮抗薬市場は、種類と用途によって区分されます。世界のムスカリン拮抗薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 アトロピン、スコポラミン、グリコピロニウム、臭化イプラトロピウム、その他 【用途別セグメント】 病院用、診療所用、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - ムスカリン拮抗薬製品概要 - 種類別市場（アトロピン、スコポラミン、グリコピロニウム、臭化イプラトロピウム、その他） - 用途別市場（病院用、診療所用、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のムスカリン拮抗薬販売量予測2017-2028 - 世界のムスカリン拮抗薬売上予測2017-2028 - ムスカリン拮抗薬の地域別販売量 - ムスカリン拮抗薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別ムスカリン拮抗薬販売量 - 主要メーカー別ムスカリン拮抗薬売上 - 主要メーカー別ムスカリン拮抗薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（アトロピン、スコポラミン、グリコピロニウム、臭化イプラトロピウム、その他） - ムスカリン拮抗薬の種類別販売量 - ムスカリン拮抗薬の種類別売上 - ムスカリン拮抗薬の種類別価格 ・用途別市場規模（病院用、診療所用、その他） - ムスカリン拮抗薬の用途別販売量 - ムスカリン拮抗薬の用途別売上 - ムスカリン拮抗薬の用途別価格 ・北米市場 - 北米のムスカリン拮抗薬市場規模（種類別、用途別） - 主要国別のムスカリン拮抗薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのムスカリン拮抗薬市場規模（種類別、用途別） - 主要国別のムスカリン拮抗薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のムスカリン拮抗薬市場規模（種類別、用途別） - 主要国別のムスカリン拮抗薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のムスカリン拮抗薬市場規模（種類別、用途別） - 主要国別のムスカリン拮抗薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのムスカリン拮抗薬市場規模（種類別、用途別） - 主要国別のムスカリン拮抗薬市場規模（トルコ、サウジアラビア） ・企業情報 Aseptic Innovative Medicine、OSRX Pharmaceuticals、Tache Pharmacy、Wufu Laboratories、Singapore National Eye Centre、Shenyang Xingqi Pharmaceutical、Aier Eye Hospital Group、He Eye Specialist Hospital、Alkaloids of Australia、Boehringer Ingelheim、Fine Chemicals Corporation、Phytex Australia、Alchem International、Guangzhou Hanfang、Alkaloids Corporation、Luyin、Toobapharma、Infa Group、Suven Life Sciences Limited、Sharon、Tai Heng Industry Co., Ltd、Stellar Chemical Laboratories Pvt、Invent Farma、Wuhan Shengtianyu、AstraZeneca、Synapse Pharma、Vectura Group、Elan ・産業チェーン及び販売チャネル分析 - ムスカリン拮抗薬の産業チェーン分析 - ムスカリン拮抗薬の原材料 - ムスカリン拮抗薬の生産プロセス - ムスカリン拮抗薬の販売及びマーケティング - ムスカリン拮抗薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - ムスカリン拮抗薬の産業動向 - ムスカリン拮抗薬のマーケットドライバー - ムスカリン拮抗薬の課題 - ムスカリン拮抗薬の阻害要因 ・主な調査結果

Market Analysis and Insights: Global Muscarinic Antagonist Market
Due to the COVID-19 pandemic, the global Muscarinic Antagonist market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Atropine accounting for % of the Muscarinic Antagonist global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Use segment is altered to an % CAGR throughout this forecast period.
China Muscarinic Antagonist market size is valued at US$ million in 2021, while the US and Europe Muscarinic Antagonist are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Muscarinic Antagonist landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Muscarinic Antagonist include Aseptic Innovative Medicine, OSRX Pharmaceuticals, Tache Pharmacy, Wufu Laboratories, Singapore National Eye Centre, Shenyang Xingqi Pharmaceutical, Aier Eye Hospital Group, He Eye Specialist Hospital and Alkaloids of Australia, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Muscarinic Antagonist Scope and Segment
Muscarinic Antagonist market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Muscarinic Antagonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Atropine
Scopolamine
Glycopyrrolate
Ipratropium Bromide
Others
Segment by Application
Hospital Use
Clinic Use
Others
By Company
Aseptic Innovative Medicine
OSRX Pharmaceuticals
Tache Pharmacy
Wufu Laboratories
Singapore National Eye Centre
Shenyang Xingqi Pharmaceutical
Aier Eye Hospital Group
He Eye Specialist Hospital
Alkaloids of Australia
Boehringer Ingelheim
Fine Chemicals Corporation
Phytex Australia
Alchem International
Guangzhou Hanfang
Alkaloids Corporation
Luyin
Toobapharma
Infa Group
Suven Life Sciences Limited
Sharon
Tai Heng Industry Co., Ltd
Stellar Chemical Laboratories Pvt
Invent Farma
Wuhan Shengtianyu
AstraZeneca
Synapse Pharma
Vectura Group
Elan
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Muscarinic Antagonist Product Introduction
1.2 Market by Type
1.2.1 Global Muscarinic Antagonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Atropine
1.2.3 Scopolamine
1.2.4 Glycopyrrolate
1.2.5 Ipratropium Bromide
1.2.6 Others
1.3 Market by Application
1.3.1 Global Muscarinic Antagonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Use
1.3.3 Clinic Use
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Muscarinic Antagonist Sales Estimates and Forecasts 2017-2028
2.2 Global Muscarinic Antagonist Revenue Estimates and Forecasts 2017-2028
2.3 Global Muscarinic Antagonist Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Muscarinic Antagonist Sales by Region
2.4.1 Global Muscarinic Antagonist Sales by Region (2017-2022)
2.4.2 Global Sales Muscarinic Antagonist by Region (2023-2028)
2.5 Global Muscarinic Antagonist Revenue by Region
2.5.1 Global Muscarinic Antagonist Revenue by Region (2017-2022)
2.5.2 Global Muscarinic Antagonist Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Muscarinic Antagonist Sales by Manufacturers
3.1.1 Global Top Muscarinic Antagonist Manufacturers by Sales (2017-2022)
3.1.2 Global Muscarinic Antagonist Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Muscarinic Antagonist in 2021
3.2 Global Muscarinic Antagonist Revenue by Manufacturers
3.2.1 Global Muscarinic Antagonist Revenue by Manufacturers (2017-2022)
3.2.2 Global Muscarinic Antagonist Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Muscarinic Antagonist Revenue in 2021
3.3 Global Muscarinic Antagonist Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Muscarinic Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Muscarinic Antagonist Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Muscarinic Antagonist Sales by Type
4.1.1 Global Muscarinic Antagonist Historical Sales by Type (2017-2022)
4.1.2 Global Muscarinic Antagonist Forecasted Sales by Type (2023-2028)
4.1.3 Global Muscarinic Antagonist Sales Market Share by Type (2017-2028)
4.2 Global Muscarinic Antagonist Revenue by Type
4.2.1 Global Muscarinic Antagonist Historical Revenue by Type (2017-2022)
4.2.2 Global Muscarinic Antagonist Forecasted Revenue by Type (2023-2028)
4.2.3 Global Muscarinic Antagonist Revenue Market Share by Type (2017-2028)
4.3 Global Muscarinic Antagonist Price by Type
4.3.1 Global Muscarinic Antagonist Price by Type (2017-2022)
4.3.2 Global Muscarinic Antagonist Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Muscarinic Antagonist Sales by Application
5.1.1 Global Muscarinic Antagonist Historical Sales by Application (2017-2022)
5.1.2 Global Muscarinic Antagonist Forecasted Sales by Application (2023-2028)
5.1.3 Global Muscarinic Antagonist Sales Market Share by Application (2017-2028)
5.2 Global Muscarinic Antagonist Revenue by Application
5.2.1 Global Muscarinic Antagonist Historical Revenue by Application (2017-2022)
5.2.2 Global Muscarinic Antagonist Forecasted Revenue by Application (2023-2028)
5.2.3 Global Muscarinic Antagonist Revenue Market Share by Application (2017-2028)
5.3 Global Muscarinic Antagonist Price by Application
5.3.1 Global Muscarinic Antagonist Price by Application (2017-2022)
5.3.2 Global Muscarinic Antagonist Price Forecast by Application (2023-2028)
6 North America
6.1 North America Muscarinic Antagonist Market Size by Type
6.1.1 North America Muscarinic Antagonist Sales by Type (2017-2028)
6.1.2 North America Muscarinic Antagonist Revenue by Type (2017-2028)
6.2 North America Muscarinic Antagonist Market Size by Application
6.2.1 North America Muscarinic Antagonist Sales by Application (2017-2028)
6.2.2 North America Muscarinic Antagonist Revenue by Application (2017-2028)
6.3 North America Muscarinic Antagonist Market Size by Country
6.3.1 North America Muscarinic Antagonist Sales by Country (2017-2028)
6.3.2 North America Muscarinic Antagonist Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Muscarinic Antagonist Market Size by Type
7.1.1 Europe Muscarinic Antagonist Sales by Type (2017-2028)
7.1.2 Europe Muscarinic Antagonist Revenue by Type (2017-2028)
7.2 Europe Muscarinic Antagonist Market Size by Application
7.2.1 Europe Muscarinic Antagonist Sales by Application (2017-2028)
7.2.2 Europe Muscarinic Antagonist Revenue by Application (2017-2028)
7.3 Europe Muscarinic Antagonist Market Size by Country
7.3.1 Europe Muscarinic Antagonist Sales by Country (2017-2028)
7.3.2 Europe Muscarinic Antagonist Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Muscarinic Antagonist Market Size by Type
8.1.1 Asia Pacific Muscarinic Antagonist Sales by Type (2017-2028)
8.1.2 Asia Pacific Muscarinic Antagonist Revenue by Type (2017-2028)
8.2 Asia Pacific Muscarinic Antagonist Market Size by Application
8.2.1 Asia Pacific Muscarinic Antagonist Sales by Application (2017-2028)
8.2.2 Asia Pacific Muscarinic Antagonist Revenue by Application (2017-2028)
8.3 Asia Pacific Muscarinic Antagonist Market Size by Region
8.3.1 Asia Pacific Muscarinic Antagonist Sales by Region (2017-2028)
8.3.2 Asia Pacific Muscarinic Antagonist Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Muscarinic Antagonist Market Size by Type
9.1.1 Latin America Muscarinic Antagonist Sales by Type (2017-2028)
9.1.2 Latin America Muscarinic Antagonist Revenue by Type (2017-2028)
9.2 Latin America Muscarinic Antagonist Market Size by Application
9.2.1 Latin America Muscarinic Antagonist Sales by Application (2017-2028)
9.2.2 Latin America Muscarinic Antagonist Revenue by Application (2017-2028)
9.3 Latin America Muscarinic Antagonist Market Size by Country
9.3.1 Latin America Muscarinic Antagonist Sales by Country (2017-2028)
9.3.2 Latin America Muscarinic Antagonist Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Muscarinic Antagonist Market Size by Type
10.1.1 Middle East and Africa Muscarinic Antagonist Sales by Type (2017-2028)
10.1.2 Middle East and Africa Muscarinic Antagonist Revenue by Type (2017-2028)
10.2 Middle East and Africa Muscarinic Antagonist Market Size by Application
10.2.1 Middle East and Africa Muscarinic Antagonist Sales by Application (2017-2028)
10.2.2 Middle East and Africa Muscarinic Antagonist Revenue by Application (2017-2028)
10.3 Middle East and Africa Muscarinic Antagonist Market Size by Country
10.3.1 Middle East and Africa Muscarinic Antagonist Sales by Country (2017-2028)
10.3.2 Middle East and Africa Muscarinic Antagonist Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Aseptic Innovative Medicine
11.1.1 Aseptic Innovative Medicine Corporation Information
11.1.2 Aseptic Innovative Medicine Overview
11.1.3 Aseptic Innovative Medicine Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Aseptic Innovative Medicine Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Aseptic Innovative Medicine Recent Developments
11.2 OSRX Pharmaceuticals
11.2.1 OSRX Pharmaceuticals Corporation Information
11.2.2 OSRX Pharmaceuticals Overview
11.2.3 OSRX Pharmaceuticals Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 OSRX Pharmaceuticals Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 OSRX Pharmaceuticals Recent Developments
11.3 Tache Pharmacy
11.3.1 Tache Pharmacy Corporation Information
11.3.2 Tache Pharmacy Overview
11.3.3 Tache Pharmacy Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Tache Pharmacy Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Tache Pharmacy Recent Developments
11.4 Wufu Laboratories
11.4.1 Wufu Laboratories Corporation Information
11.4.2 Wufu Laboratories Overview
11.4.3 Wufu Laboratories Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Wufu Laboratories Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Wufu Laboratories Recent Developments
11.5 Singapore National Eye Centre
11.5.1 Singapore National Eye Centre Corporation Information
11.5.2 Singapore National Eye Centre Overview
11.5.3 Singapore National Eye Centre Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Singapore National Eye Centre Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Singapore National Eye Centre Recent Developments
11.6 Shenyang Xingqi Pharmaceutical
11.6.1 Shenyang Xingqi Pharmaceutical Corporation Information
11.6.2 Shenyang Xingqi Pharmaceutical Overview
11.6.3 Shenyang Xingqi Pharmaceutical Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Shenyang Xingqi Pharmaceutical Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Shenyang Xingqi Pharmaceutical Recent Developments
11.7 Aier Eye Hospital Group
11.7.1 Aier Eye Hospital Group Corporation Information
11.7.2 Aier Eye Hospital Group Overview
11.7.3 Aier Eye Hospital Group Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Aier Eye Hospital Group Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Aier Eye Hospital Group Recent Developments
11.8 He Eye Specialist Hospital
11.8.1 He Eye Specialist Hospital Corporation Information
11.8.2 He Eye Specialist Hospital Overview
11.8.3 He Eye Specialist Hospital Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 He Eye Specialist Hospital Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 He Eye Specialist Hospital Recent Developments
11.9 Alkaloids of Australia
11.9.1 Alkaloids of Australia Corporation Information
11.9.2 Alkaloids of Australia Overview
11.9.3 Alkaloids of Australia Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Alkaloids of Australia Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Alkaloids of Australia Recent Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Corporation Information
11.10.2 Boehringer Ingelheim Overview
11.10.3 Boehringer Ingelheim Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Boehringer Ingelheim Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Boehringer Ingelheim Recent Developments
11.11 Fine Chemicals Corporation
11.11.1 Fine Chemicals Corporation Corporation Information
11.11.2 Fine Chemicals Corporation Overview
11.11.3 Fine Chemicals Corporation Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Fine Chemicals Corporation Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Fine Chemicals Corporation Recent Developments
11.12 Phytex Australia
11.12.1 Phytex Australia Corporation Information
11.12.2 Phytex Australia Overview
11.12.3 Phytex Australia Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Phytex Australia Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Phytex Australia Recent Developments
11.13 Alchem International
11.13.1 Alchem International Corporation Information
11.13.2 Alchem International Overview
11.13.3 Alchem International Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Alchem International Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Alchem International Recent Developments
11.14 Guangzhou Hanfang
11.14.1 Guangzhou Hanfang Corporation Information
11.14.2 Guangzhou Hanfang Overview
11.14.3 Guangzhou Hanfang Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Guangzhou Hanfang Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Guangzhou Hanfang Recent Developments
11.15 Alkaloids Corporation
11.15.1 Alkaloids Corporation Corporation Information
11.15.2 Alkaloids Corporation Overview
11.15.3 Alkaloids Corporation Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Alkaloids Corporation Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Alkaloids Corporation Recent Developments
11.16 Luyin
11.16.1 Luyin Corporation Information
11.16.2 Luyin Overview
11.16.3 Luyin Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Luyin Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Luyin Recent Developments
11.17 Toobapharma
11.17.1 Toobapharma Corporation Information
11.17.2 Toobapharma Overview
11.17.3 Toobapharma Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Toobapharma Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Toobapharma Recent Developments
11.18 Infa Group
11.18.1 Infa Group Corporation Information
11.18.2 Infa Group Overview
11.18.3 Infa Group Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Infa Group Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Infa Group Recent Developments
11.19 Suven Life Sciences Limited
11.19.1 Suven Life Sciences Limited Corporation Information
11.19.2 Suven Life Sciences Limited Overview
11.19.3 Suven Life Sciences Limited Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Suven Life Sciences Limited Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Suven Life Sciences Limited Recent Developments
11.20 Sharon
11.20.1 Sharon Corporation Information
11.20.2 Sharon Overview
11.20.3 Sharon Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Sharon Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Sharon Recent Developments
11.21 Tai Heng Industry Co., Ltd
11.21.1 Tai Heng Industry Co., Ltd Corporation Information
11.21.2 Tai Heng Industry Co., Ltd Overview
11.21.3 Tai Heng Industry Co., Ltd Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Tai Heng Industry Co., Ltd Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Tai Heng Industry Co., Ltd Recent Developments
11.22 Stellar Chemical Laboratories Pvt
11.22.1 Stellar Chemical Laboratories Pvt Corporation Information
11.22.2 Stellar Chemical Laboratories Pvt Overview
11.22.3 Stellar Chemical Laboratories Pvt Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 Stellar Chemical Laboratories Pvt Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 Stellar Chemical Laboratories Pvt Recent Developments
11.23 Invent Farma
11.23.1 Invent Farma Corporation Information
11.23.2 Invent Farma Overview
11.23.3 Invent Farma Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.23.4 Invent Farma Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.23.5 Invent Farma Recent Developments
11.24 Wuhan Shengtianyu
11.24.1 Wuhan Shengtianyu Corporation Information
11.24.2 Wuhan Shengtianyu Overview
11.24.3 Wuhan Shengtianyu Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.24.4 Wuhan Shengtianyu Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.24.5 Wuhan Shengtianyu Recent Developments
11.25 AstraZeneca
11.25.1 AstraZeneca Corporation Information
11.25.2 AstraZeneca Overview
11.25.3 AstraZeneca Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.25.4 AstraZeneca Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.25.5 AstraZeneca Recent Developments
11.26 Synapse Pharma
11.26.1 Synapse Pharma Corporation Information
11.26.2 Synapse Pharma Overview
11.26.3 Synapse Pharma Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.26.4 Synapse Pharma Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.26.5 Synapse Pharma Recent Developments
11.27 Vectura Group
11.27.1 Vectura Group Corporation Information
11.27.2 Vectura Group Overview
11.27.3 Vectura Group Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.27.4 Vectura Group Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.27.5 Vectura Group Recent Developments
11.28 Elan
11.28.1 Elan Corporation Information
11.28.2 Elan Overview
11.28.3 Elan Muscarinic Antagonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.28.4 Elan Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.28.5 Elan Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Muscarinic Antagonist Industry Chain Analysis
12.2 Muscarinic Antagonist Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Muscarinic Antagonist Production Mode & Process
12.4 Muscarinic Antagonist Sales and Marketing
12.4.1 Muscarinic Antagonist Sales Channels
12.4.2 Muscarinic Antagonist Distributors
12.5 Muscarinic Antagonist Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Muscarinic Antagonist Industry Trends
13.2 Muscarinic Antagonist Market Drivers
13.3 Muscarinic Antagonist Market Challenges
13.4 Muscarinic Antagonist Market Restraints
14 Key Findings in The Global Muscarinic Antagonist Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Muscarinic Antagonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Atropine
Table 3. Major Manufacturers of Scopolamine
Table 4. Major Manufacturers of Glycopyrrolate
Table 5. Major Manufacturers of Ipratropium Bromide
Table 6. Major Manufacturers of Others
Table 7. Global Muscarinic Antagonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Muscarinic Antagonist Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Muscarinic Antagonist Sales by Region (2017-2022) & (K Units)
Table 10. Global Muscarinic Antagonist Sales Market Share by Region (2017-2022)
Table 11. Global Muscarinic Antagonist Sales by Region (2023-2028) & (K Units)
Table 12. Global Muscarinic Antagonist Sales Market Share by Region (2023-2028)
Table 13. Global Muscarinic Antagonist Revenue by Region (2017-2022) & (US$ Million)
Table 14. Global Muscarinic Antagonist Revenue Market Share by Region (2017-2022)
Table 15. Global Muscarinic Antagonist Revenue by Region (2023-2028) & (US$ Million)
Table 16. Global Muscarinic Antagonist Revenue Market Share by Region (2023-2028)
Table 17. Global Muscarinic Antagonist Sales by Manufacturers (2017-2022) & (K Units)
Table 18. Global Muscarinic Antagonist Sales Share by Manufacturers (2017-2022)
Table 19. Global Muscarinic Antagonist Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 20. Global Muscarinic Antagonist Revenue Share by Manufacturers (2017-2022)
Table 21. Muscarinic Antagonist Price by Manufacturers (2017-2022) &(US$/Unit)
Table 22. Global Muscarinic Antagonist Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Muscarinic Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Muscarinic Antagonist as of 2021)
Table 24. Muscarinic Antagonist Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Muscarinic Antagonist Product Offered
Table 26. Date of Manufacturers Enter into Muscarinic Antagonist Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Muscarinic Antagonist Sales by Type (2017-2022) & (K Units)
Table 29. Global Muscarinic Antagonist Sales by Type (2023-2028) & (K Units)
Table 30. Global Muscarinic Antagonist Sales Share by Type (2017-2022)
Table 31. Global Muscarinic Antagonist Sales Share by Type (2023-2028)
Table 32. Global Muscarinic Antagonist Revenue by Type (2017-2022) & (US$ Million)
Table 33. Global Muscarinic Antagonist Revenue by Type (2023-2028) & (US$ Million)
Table 34. Global Muscarinic Antagonist Revenue Share by Type (2017-2022)
Table 35. Global Muscarinic Antagonist Revenue Share by Type (2023-2028)
Table 36. Muscarinic Antagonist Price by Type (2017-2022) & (US$/Unit)
Table 37. Global Muscarinic Antagonist Price Forecast by Type (2023-2028) & (US$/Unit)
Table 38. Global Muscarinic Antagonist Sales by Application (2017-2022) & (K Units)
Table 39. Global Muscarinic Antagonist Sales by Application (2023-2028) & (K Units)
Table 40. Global Muscarinic Antagonist Sales Share by Application (2017-2022)
Table 41. Global Muscarinic Antagonist Sales Share by Application (2023-2028)
Table 42. Global Muscarinic Antagonist Revenue by Application (2017-2022) & (US$ Million)
Table 43. Global Muscarinic Antagonist Revenue by Application (2023-2028) & (US$ Million)
Table 44. Global Muscarinic Antagonist Revenue Share by Application (2017-2022)
Table 45. Global Muscarinic Antagonist Revenue Share by Application (2023-2028)
Table 46. Muscarinic Antagonist Price by Application (2017-2022) & (US$/Unit)
Table 47. Global Muscarinic Antagonist Price Forecast by Application (2023-2028) & (US$/Unit)
Table 48. North America Muscarinic Antagonist Sales by Type (2017-2022) & (K Units)
Table 49. North America Muscarinic Antagonist Sales by Type (2023-2028) & (K Units)
Table 50. North America Muscarinic Antagonist Revenue by Type (2017-2022) & (US$ Million)
Table 51. North America Muscarinic Antagonist Revenue by Type (2023-2028) & (US$ Million)
Table 52. North America Muscarinic Antagonist Sales by Application (2017-2022) & (K Units)
Table 53. North America Muscarinic Antagonist Sales by Application (2023-2028) & (K Units)
Table 54. North America Muscarinic Antagonist Revenue by Application (2017-2022) & (US$ Million)
Table 55. North America Muscarinic Antagonist Revenue by Application (2023-2028) & (US$ Million)
Table 56. North America Muscarinic Antagonist Sales by Country (2017-2022) & (K Units)
Table 57. North America Muscarinic Antagonist Sales by Country (2023-2028) & (K Units)
Table 58. North America Muscarinic Antagonist Revenue by Country (2017-2022) & (US$ Million)
Table 59. North America Muscarinic Antagonist Revenue by Country (2023-2028) & (US$ Million)
Table 60. Europe Muscarinic Antagonist Sales by Type (2017-2022) & (K Units)
Table 61. Europe Muscarinic Antagonist Sales by Type (2023-2028) & (K Units)
Table 62. Europe Muscarinic Antagonist Revenue by Type (2017-2022) & (US$ Million)
Table 63. Europe Muscarinic Antagonist Revenue by Type (2023-2028) & (US$ Million)
Table 64. Europe Muscarinic Antagonist Sales by Application (2017-2022) & (K Units)
Table 65. Europe Muscarinic Antagonist Sales by Application (2023-2028) & (K Units)
Table 66. Europe Muscarinic Antagonist Revenue by Application (2017-2022) & (US$ Million)
Table 67. Europe Muscarinic Antagonist Revenue by Application (2023-2028) & (US$ Million)
Table 68. Europe Muscarinic Antagonist Sales by Country (2017-2022) & (K Units)
Table 69. Europe Muscarinic Antagonist Sales by Country (2023-2028) & (K Units)
Table 70. Europe Muscarinic Antagonist Revenue by Country (2017-2022) & (US$ Million)
Table 71. Europe Muscarinic Antagonist Revenue by Country (2023-2028) & (US$ Million)
Table 72. Asia Pacific Muscarinic Antagonist Sales by Type (2017-2022) & (K Units)
Table 73. Asia Pacific Muscarinic Antagonist Sales by Type (2023-2028) & (K Units)
Table 74. Asia Pacific Muscarinic Antagonist Revenue by Type (2017-2022) & (US$ Million)
Table 75. Asia Pacific Muscarinic Antagonist Revenue by Type (2023-2028) & (US$ Million)
Table 76. Asia Pacific Muscarinic Antagonist Sales by Application (2017-2022) & (K Units)
Table 77. Asia Pacific Muscarinic Antagonist Sales by Application (2023-2028) & (K Units)
Table 78. Asia Pacific Muscarinic Antagonist Revenue by Application (2017-2022) & (US$ Million)
Table 79. Asia Pacific Muscarinic Antagonist Revenue by Application (2023-2028) & (US$ Million)
Table 80. Asia Pacific Muscarinic Antagonist Sales by Region (2017-2022) & (K Units)
Table 81. Asia Pacific Muscarinic Antagonist Sales by Region (2023-2028) & (K Units)
Table 82. Asia Pacific Muscarinic Antagonist Revenue by Region (2017-2022) & (US$ Million)
Table 83. Asia Pacific Muscarinic Antagonist Revenue by Region (2023-2028) & (US$ Million)
Table 84. Latin America Muscarinic Antagonist Sales by Type (2017-2022) & (K Units)
Table 85. Latin America Muscarinic Antagonist Sales by Type (2023-2028) & (K Units)
Table 86. Latin America Muscarinic Antagonist Revenue by Type (2017-2022) & (US$ Million)
Table 87. Latin America Muscarinic Antagonist Revenue by Type (2023-2028) & (US$ Million)
Table 88. Latin America Muscarinic Antagonist Sales by Application (2017-2022) & (K Units)
Table 89. Latin America Muscarinic Antagonist Sales by Application (2023-2028) & (K Units)
Table 90. Latin America Muscarinic Antagonist Revenue by Application (2017-2022) & (US$ Million)
Table 91. Latin America Muscarinic Antagonist Revenue by Application (2023-2028) & (US$ Million)
Table 92. Latin America Muscarinic Antagonist Sales by Country (2017-2022) & (K Units)
Table 93. Latin America Muscarinic Antagonist Sales by Country (2023-2028) & (K Units)
Table 94. Latin America Muscarinic Antagonist Revenue by Country (2017-2022) & (US$ Million)
Table 95. Latin America Muscarinic Antagonist Revenue by Country (2023-2028) & (US$ Million)
Table 96. Middle East and Africa Muscarinic Antagonist Sales by Type (2017-2022) & (K Units)
Table 97. Middle East and Africa Muscarinic Antagonist Sales by Type (2023-2028) & (K Units)
Table 98. Middle East and Africa Muscarinic Antagonist Revenue by Type (2017-2022) & (US$ Million)
Table 99. Middle East and Africa Muscarinic Antagonist Revenue by Type (2023-2028) & (US$ Million)
Table 100. Middle East and Africa Muscarinic Antagonist Sales by Application (2017-2022) & (K Units)
Table 101. Middle East and Africa Muscarinic Antagonist Sales by Application (2023-2028) & (K Units)
Table 102. Middle East and Africa Muscarinic Antagonist Revenue by Application (2017-2022) & (US$ Million)
Table 103. Middle East and Africa Muscarinic Antagonist Revenue by Application (2023-2028) & (US$ Million)
Table 104. Middle East and Africa Muscarinic Antagonist Sales by Country (2017-2022) & (K Units)
Table 105. Middle East and Africa Muscarinic Antagonist Sales by Country (2023-2028) & (K Units)
Table 106. Middle East and Africa Muscarinic Antagonist Revenue by Country (2017-2022) & (US$ Million)
Table 107. Middle East and Africa Muscarinic Antagonist Revenue by Country (2023-2028) & (US$ Million)
Table 108. Aseptic Innovative Medicine Corporation Information
Table 109. Aseptic Innovative Medicine Description and Major Businesses
Table 110. Aseptic Innovative Medicine Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 111. Aseptic Innovative Medicine Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Aseptic Innovative Medicine Recent Developments
Table 113. OSRX Pharmaceuticals Corporation Information
Table 114. OSRX Pharmaceuticals Description and Major Businesses
Table 115. OSRX Pharmaceuticals Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 116. OSRX Pharmaceuticals Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. OSRX Pharmaceuticals Recent Developments
Table 118. Tache Pharmacy Corporation Information
Table 119. Tache Pharmacy Description and Major Businesses
Table 120. Tache Pharmacy Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 121. Tache Pharmacy Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Tache Pharmacy Recent Developments
Table 123. Wufu Laboratories Corporation Information
Table 124. Wufu Laboratories Description and Major Businesses
Table 125. Wufu Laboratories Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 126. Wufu Laboratories Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Wufu Laboratories Recent Developments
Table 128. Singapore National Eye Centre Corporation Information
Table 129. Singapore National Eye Centre Description and Major Businesses
Table 130. Singapore National Eye Centre Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 131. Singapore National Eye Centre Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Singapore National Eye Centre Recent Developments
Table 133. Shenyang Xingqi Pharmaceutical Corporation Information
Table 134. Shenyang Xingqi Pharmaceutical Description and Major Businesses
Table 135. Shenyang Xingqi Pharmaceutical Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 136. Shenyang Xingqi Pharmaceutical Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Shenyang Xingqi Pharmaceutical Recent Developments
Table 138. Aier Eye Hospital Group Corporation Information
Table 139. Aier Eye Hospital Group Description and Major Businesses
Table 140. Aier Eye Hospital Group Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 141. Aier Eye Hospital Group Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Aier Eye Hospital Group Recent Developments
Table 143. He Eye Specialist Hospital Corporation Information
Table 144. He Eye Specialist Hospital Description and Major Businesses
Table 145. He Eye Specialist Hospital Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 146. He Eye Specialist Hospital Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. He Eye Specialist Hospital Recent Developments
Table 148. Alkaloids of Australia Corporation Information
Table 149. Alkaloids of Australia Description and Major Businesses
Table 150. Alkaloids of Australia Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 151. Alkaloids of Australia Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Alkaloids of Australia Recent Developments
Table 153. Boehringer Ingelheim Corporation Information
Table 154. Boehringer Ingelheim Description and Major Businesses
Table 155. Boehringer Ingelheim Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 156. Boehringer Ingelheim Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Boehringer Ingelheim Recent Developments
Table 158. Fine Chemicals Corporation Corporation Information
Table 159. Fine Chemicals Corporation Description and Major Businesses
Table 160. Fine Chemicals Corporation Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 161. Fine Chemicals Corporation Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. Fine Chemicals Corporation Recent Developments
Table 163. Phytex Australia Corporation Information
Table 164. Phytex Australia Description and Major Businesses
Table 165. Phytex Australia Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 166. Phytex Australia Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. Phytex Australia Recent Developments
Table 168. Alchem International Corporation Information
Table 169. Alchem International Description and Major Businesses
Table 170. Alchem International Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 171. Alchem International Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 172. Alchem International Recent Developments
Table 173. Guangzhou Hanfang Corporation Information
Table 174. Guangzhou Hanfang Description and Major Businesses
Table 175. Guangzhou Hanfang Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 176. Guangzhou Hanfang Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 177. Guangzhou Hanfang Recent Developments
Table 178. Alkaloids Corporation Corporation Information
Table 179. Alkaloids Corporation Description and Major Businesses
Table 180. Alkaloids Corporation Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 181. Alkaloids Corporation Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 182. Alkaloids Corporation Recent Developments
Table 183. Luyin Corporation Information
Table 184. Luyin Description and Major Businesses
Table 185. Luyin Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 186. Luyin Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 187. Luyin Recent Developments
Table 188. Toobapharma Corporation Information
Table 189. Toobapharma Description and Major Businesses
Table 190. Toobapharma Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 191. Toobapharma Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 192. Toobapharma Recent Developments
Table 193. Infa Group Corporation Information
Table 194. Infa Group Description and Major Businesses
Table 195. Infa Group Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 196. Infa Group Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 197. Infa Group Recent Developments
Table 198. Suven Life Sciences Limited Corporation Information
Table 199. Suven Life Sciences Limited Description and Major Businesses
Table 200. Suven Life Sciences Limited Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 201. Suven Life Sciences Limited Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 202. Suven Life Sciences Limited Recent Developments
Table 203. Sharon Corporation Information
Table 204. Sharon Description and Major Businesses
Table 205. Sharon Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 206. Sharon Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 207. Sharon Recent Developments
Table 208. Tai Heng Industry Co., Ltd Corporation Information
Table 209. Tai Heng Industry Co., Ltd Description and Major Businesses
Table 210. Tai Heng Industry Co., Ltd Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 211. Tai Heng Industry Co., Ltd Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 212. Tai Heng Industry Co., Ltd Recent Developments
Table 213. Stellar Chemical Laboratories Pvt Corporation Information
Table 214. Stellar Chemical Laboratories Pvt Description and Major Businesses
Table 215. Stellar Chemical Laboratories Pvt Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 216. Stellar Chemical Laboratories Pvt Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 217. Stellar Chemical Laboratories Pvt Recent Developments
Table 218. Invent Farma Corporation Information
Table 219. Invent Farma Description and Major Businesses
Table 220. Invent Farma Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 221. Invent Farma Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 222. Invent Farma Recent Developments
Table 223. Wuhan Shengtianyu Corporation Information
Table 224. Wuhan Shengtianyu Description and Major Businesses
Table 225. Wuhan Shengtianyu Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 226. Wuhan Shengtianyu Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 227. Wuhan Shengtianyu Recent Developments
Table 228. AstraZeneca Corporation Information
Table 229. AstraZeneca Description and Major Businesses
Table 230. AstraZeneca Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 231. AstraZeneca Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 232. AstraZeneca Recent Developments
Table 233. Synapse Pharma Corporation Information
Table 234. Synapse Pharma Description and Major Businesses
Table 235. Synapse Pharma Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 236. Synapse Pharma Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 237. Synapse Pharma Recent Developments
Table 238. Vectura Group Corporation Information
Table 239. Vectura Group Description and Major Businesses
Table 240. Vectura Group Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 241. Vectura Group Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 242. Vectura Group Recent Developments
Table 243. Elan Corporation Information
Table 244. Elan Description and Major Businesses
Table 245. Elan Muscarinic Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 246. Elan Muscarinic Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 247. Elan Recent Developments
Table 248. Key Raw Materials Lists
Table 249. Raw Materials Key Suppliers Lists
Table 250. Muscarinic Antagonist Distributors List
Table 251. Muscarinic Antagonist Customers List
Table 252. Muscarinic Antagonist Market Trends
Table 253. Muscarinic Antagonist Market Drivers
Table 254. Muscarinic Antagonist Market Challenges
Table 255. Muscarinic Antagonist Market Restraints
Table 256. Research Programs/Design for This Report
Table 257. Key Data Information from Secondary Sources
Table 258. Key Data Information from Primary Sources
List of Figures
Figure 1. Muscarinic Antagonist Product Picture
Figure 3. Global Muscarinic Antagonist Market Share by Type in 2021 & 2028
Figure 3. Atropine Product Picture
Figure 4. Scopolamine Product Picture
Figure 5. Glycopyrrolate Product Picture
Figure 6. Ipratropium Bromide Product Picture
Figure 7. Others Product Picture
Figure 8. Global Muscarinic Antagonist Market Share by Application in 2021 & 2028
Figure 9. Hospital Use
Figure 10. Clinic Use
Figure 11. Others
Figure 12. Muscarinic Antagonist Report Years Considered
Figure 13. Global Muscarinic Antagonist Sales 2017-2028 (K Units)
Figure 14. Global Muscarinic Antagonist Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Muscarinic Antagonist Revenue 2017-2028 (US$ Million)
Figure 16. Global Muscarinic Antagonist Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 17. Global Muscarinic Antagonist Sales Market Share by Region (2017-2022)
Figure 18. Global Muscarinic Antagonist Sales Market Share by Region (2023-2028)
Figure 19. North America Muscarinic Antagonist Sales YoY (2017-2028) & (K Units)
Figure 20. North America Muscarinic Antagonist Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Europe Muscarinic Antagonist Sales YoY (2017-2028) & (K Units)
Figure 22. Europe Muscarinic Antagonist Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Asia-Pacific Muscarinic Antagonist Sales YoY (2017-2028) & (K Units)
Figure 24. Asia-Pacific Muscarinic Antagonist Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Latin America Muscarinic Antagonist Sales YoY (2017-2028) & (K Units)
Figure 26. Latin America Muscarinic Antagonist Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Middle East & Africa Muscarinic Antagonist Sales YoY (2017-2028) & (K Units)
Figure 28. Middle East & Africa Muscarinic Antagonist Revenue YoY (2017-2028) & (US$ Million)
Figure 29. The Muscarinic Antagonist Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 30. The Top 5 and 10 Largest Manufacturers of Muscarinic Antagonist in the World: Market Share by Muscarinic Antagonist Revenue in 2021
Figure 31. Global Muscarinic Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 32. Global Muscarinic Antagonist Sales Market Share by Type (2017-2028)
Figure 33. Global Muscarinic Antagonist Revenue Market Share by Type (2017-2028)
Figure 34. Global Muscarinic Antagonist Sales Market Share by Application (2017-2028)
Figure 35. Global Muscarinic Antagonist Revenue Market Share by Application (2017-2028)
Figure 36. North America Muscarinic Antagonist Sales Market Share by Type (2017-2028)
Figure 37. North America Muscarinic Antagonist Revenue Market Share by Type (2017-2028)
Figure 38. North America Muscarinic Antagonist Sales Market Share by Application (2017-2028)
Figure 39. North America Muscarinic Antagonist Revenue Market Share by Application (2017-2028)
Figure 40. North America Muscarinic Antagonist Sales Share by Country (2017-2028)
Figure 41. North America Muscarinic Antagonist Revenue Share by Country (2017-2028)
Figure 42. United States Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 43. Canada Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 44. Europe Muscarinic Antagonist Sales Market Share by Type (2017-2028)
Figure 45. Europe Muscarinic Antagonist Revenue Market Share by Type (2017-2028)
Figure 46. Europe Muscarinic Antagonist Sales Market Share by Application (2017-2028)
Figure 47. Europe Muscarinic Antagonist Revenue Market Share by Application (2017-2028)
Figure 48. Europe Muscarinic Antagonist Sales Share by Country (2017-2028)
Figure 49. Europe Muscarinic Antagonist Revenue Share by Country (2017-2028)
Figure 50. Germany Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 51. France Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 52. U.K. Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 53. Italy Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 54. Russia Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 55. Asia Pacific Muscarinic Antagonist Sales Market Share by Type (2017-2028)
Figure 56. Asia Pacific Muscarinic Antagonist Revenue Market Share by Type (2017-2028)
Figure 57. Asia Pacific Muscarinic Antagonist Sales Market Share by Application (2017-2028)
Figure 58. Asia Pacific Muscarinic Antagonist Revenue Market Share by Application (2017-2028)
Figure 59. Asia Pacific Muscarinic Antagonist Sales Share by Region (2017-2028)
Figure 60. Asia Pacific Muscarinic Antagonist Revenue Share by Region (2017-2028)
Figure 61. China Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 62. Japan Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 63. South Korea Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 64. India Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 65. Australia Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 66. China Taiwan Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 67. Indonesia Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 68. Thailand Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 69. Malaysia Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 70. Latin America Muscarinic Antagonist Sales Market Share by Type (2017-2028)
Figure 71. Latin America Muscarinic Antagonist Revenue Market Share by Type (2017-2028)
Figure 72. Latin America Muscarinic Antagonist Sales Market Share by Application (2017-2028)
Figure 73. Latin America Muscarinic Antagonist Revenue Market Share by Application (2017-2028)
Figure 74. Latin America Muscarinic Antagonist Sales Share by Country (2017-2028)
Figure 75. Latin America Muscarinic Antagonist Revenue Share by Country (2017-2028)
Figure 76. Mexico Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 77. Brazil Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 78. Argentina Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 79. Middle East and Africa Muscarinic Antagonist Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Muscarinic Antagonist Revenue Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Muscarinic Antagonist Sales Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Muscarinic Antagonist Revenue Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Muscarinic Antagonist Sales Share by Country (2017-2028)
Figure 84. Middle East and Africa Muscarinic Antagonist Revenue Share by Country (2017-2028)
Figure 85. Turkey Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 86. Saudi Arabia Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 87. UAE Muscarinic Antagonist Revenue (2017-2028) & (US$ Million)
Figure 88. Muscarinic Antagonist Value Chain
Figure 89. Muscarinic Antagonist Production Process
Figure 90. Channels of Distribution
Figure 91. Distributors Profiles
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed

---